Study: Estrogen-blocking drugs work for patients with breast cancer

08/18/2011 | EurekAlert!

PET imaging with 18F-fluoroestradiol showed that estrogen-receptor-blocking drugs such as tamoxifen and fulvestrant performed better than estrogen-eliminating drugs in stopping estrogen receptor in cancer cells of patients with breast cancer metastasis to the bones, according to a study published in Clinical Cancer Research. Tamoxifen also proved to be more effective than fulvestrant in hindering estrogen, according to the study. "Our findings support the ability of FES-PET to visualize the in vivo activity of endocrine therapy," the researchers said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ